Chai Discovery's $130M Series B and the open-source Chai-1 protein-structure model put the category back in conversation against AlphaFold 3 and Isomorphic Labs. Recursion and Tempus operate the largest phenomics and clinical-genomics datasets in the public-comparable set, while Insilico Medicine pushed its first generative-AI-designed molecule INS018_055 into Phase II for IPF. Owkin partners with hospitals on federated learning, EvolutionaryScale shipped ESM3 as a frontier protein language model, and Xaira Therapeutics launched in 2024 with one of the largest seed rounds in biotech history. Atomwise, Cradle, Latent Labs, and Iambic round out the computational-chemistry layer.
CATEGORY
Best Drug Discovery AI Tools
61 tools compared · 2026
Generative chemistry, protein language models, and AI scientists targeting the trillion-dollar pharma R&D bottleneck
61 drug discovery startups tracked, with the largest concentration in US. Total tracked funding: $9.5B.
Tracked
61
Total Raised
$9.5B
Countries
9
Active Deals
0
1 
Isomorphic Labs — $2.7B 2 
Generate:Biomedicines Somerville, United States $700M 3 
Proscia Philadelphia, United States $130M 4 
Genesis Therapeutics — $344M 5 
Aqemia — $103M 6 
Chemify Glasgow, United Kingdom $93M 7 
Cellular Intelligence Boston, United States $47M 8 
Tahoe Therapeutics — $30M 9 
Accipiter Biosciences Seattle, United States $12.7M 10 
Axiom Bio San Francisco, United States $15M 11 
Yoneda Labs San Francisco, United States $4M 12 
Recursion Salt Lake City, US $500M
Funding by year — Drug Discovery
2019 → 2026Market overview
Key trends 2026
- Foundation-model biology arrives. Chai-1, ESM3, and AlphaFold 3 reset the structure-prediction baseline for in silico screening.
- Phase II readouts begin. Insilico's INS018_055 IPF program gives the first generative-AI-discovered drug a real clinical signal.
- Federated data beats centralized scraping. Owkin's hospital network model sidesteps the patient-data licensing wall that blocks others.
Benchmarks vs global
First AI-designed drug in Phase II
INS018_055 (Insilico)
vs zero pre-2023 ↑
Largest tracked round
$130M (Chai Series B)
vs Xaira's $1B 2024 launch ↑
Hit-rate uplift, AI-led campaigns
4-10x (Enveda claim)
vs traditional HTS baseline ↑
Top countries
By startup countStage breakdown
Latest round typeTop investors backing Drug Discovery
See all →Lux Capital
6 deals
General Catalyst
6 deals
GV (Google Ventures)
6 deals
SP
Sofinnova Partners
5 deals
AV
ARCH Venture Partners
5 deals
Khosla Ventures
5 deals
MC
Mubadala Capital
3 deals
F
F-Prime
3 deals
B
Bpifrance
3 deals
BL
Bpifrance Large Venture
3 deals
CI
Cathay Innovation
3 deals
Menlo Ventures
3 deals
FAQ
Frequently asked
Which AI drug-discovery startup has raised the most?
Among our tracked startups Chai Discovery leads at $130M Series B. Public peers Recursion and Tempus have raised more historically (Recursion $400M+ pre-IPO, Tempus IPO 2024) but trade as listed companies rather than VC-staged startups.
Has any AI-designed drug reached clinical trials?
Yes. Insilico Medicine's INS018_055 for idiopathic pulmonary fibrosis advanced into Phase II — the first molecule with both target identified and structure designed by generative AI to reach that stage. Several Recursion and Iambic candidates are in Phase I.
What does Chai-1 give researchers that AlphaFold 3 doesn't?
Chai-1 ships with weights downloadable for non-commercial research and matches AlphaFold 3 on ligand and antibody benchmarks. AlphaFold 3 is gated behind Isomorphic's web server with usage caps, which limits high-throughput in-silico screening pipelines.
Recent rounds in Drug Discovery
All rounds →| Date | Startup | Round | Amount |
|---|---|---|---|
| Jun 2026 | Apoha | Series A | $36M |
| May 2026 | Perceptic | Seed | $12M |
| May 2026 | Genesis Therapeutics | Strategic Equity Investment | $40M |
| May 2026 | Imperagen | Seed | $6.7M |
| May 2026 | Isomorphic Labs | Series B | $2.1B |
| Jan 2026 | Enjamb Labs | Seed | $500K |
| Dec 2025 | Chai Discovery | Series B | $130M |
| Dec 2025 | Paradigm Health | Series B | $78M |
All Drug Discovery startups
Page 1Isomorphic Labs
London-based AI drug-design company spun out of Google DeepMind to reimagine the entire drug
Raised
$2.7B
Stage
S-B
Generate:Biomedicines
PRIVATEGenerative AI for programmable protein therapeutics
Raised
$700M
Stage
S-C
Proscia
AI-powered digital pathology for precision medicine
Raised
$130M
Stage
S-D
Genesis Therapeutics
AI drug-discovery company building generative and predictive models to design small-molecule
Raised
$344M
Stage
STRATEGIC EQUITY INVESTMENT
Aqemia
French AI drug-discovery company that fuses quantum-inspired statistical mechanics with deep
Raised
$103M
Stage
S-B
Tahoe Therapeutics
Tahoe Therapeutics, formerly Vevo Therapeutics, builds gigascale single-cell datasets to train
Raised
$30M
Stage
S-A
Cellular Intelligence
Foundation models for human stem cells to industrialize cell therapy production
Raised
$47M
Stage
S-A
Chemify
Digitizing chemistry with AI and robotics to make any molecule on demand
Raised
$93M
Stage
S-B
Accipiter Biosciences
AI-designed de novo protein therapies for complex diseases
Raised
$12.7M
Stage
Seed
Yoneda Labs
Foundation AI model for chemistry
Raised
$4M
Stage
Seed
Axiom Bio
AI models that predict human drug toxicity without animal testing
Raised
$15M
Stage
Seed
Recursion
Pioneering AI-driven solutions in drug discovery to radically improve lives.
Raised
$500M
Stage
IPO
Alchemab Therapeutics
UK biotech using machine learning to mine patient-derived immune responses for protective
Raised
$32M
Stage
S-A
Paradigm Health
AI research platform making clinical trials part of routine patient care
Raised
$359M
Stage
S-B
Adaptyv Bio
Cloud lab that experimentally validates AI-designed proteins in under three weeks
Raised
$8M
Stage
Seed
Treeline Biosciences
Computational and experimental drug discovery for hard-to-drug cancer targets
Raised
$1.1B
Stage
S-A
Ollin Biosciences
Biotech advancing best-in-class bispecific antibody therapies for eye disease, using AI and
Raised
$100M
Stage
S-A
Lindus Health
The anti-CRO running radically faster, AI-enabled clinical trials end to end
Raised
$78M
Stage
S-B
Edison Scientific
AI scientist that compresses months of research into a single day
Raised
$70M
Stage
Seed
Bioptimus
Building the first universal AI foundation model for biology.
Raised
$76M
Stage
S-A
Ensocell
Cambridge, UK biotech that integrates single-cell and spatial genomics with AI to discover
Raised
$16.3M
Stage
Seed
Genesis Molecular AI
Generative AI for small-molecule drug discovery
Raised
$280M
Stage
S-B
Manas AI
AI-driven discovery of novel cancer medicines
Raised
$24.6M
Stage
Seed
Pathos AI
Patient-centric, AI-powered drug development company focused on accelerating cancer therapies
Raised
$467M
Stage
S-D